| Primary |
| Hypertension |
52.3% |
| Benign Prostatic Hyperplasia |
17.4% |
| Prostatic Disorder |
3.9% |
| Sepsis |
3.4% |
| Myocardial Ischaemia |
2.4% |
| Atrial Fibrillation |
2.0% |
| Blood Cholesterol Increased |
1.8% |
| Blood Pressure |
1.8% |
| Blood Pressure Increased |
1.8% |
| Osteoarthritis |
1.5% |
| Prophylaxis |
1.5% |
| Prostatomegaly |
1.5% |
| Depression |
1.3% |
| Cardiac Disorder |
1.1% |
| Diabetes Mellitus |
1.1% |
| Epilepsy |
1.1% |
| Ill-defined Disorder |
1.1% |
| Anticoagulant Therapy |
1.0% |
| Drug Use For Unknown Indication |
1.0% |
| Hypertensive Heart Disease |
1.0% |
|
| Syncope |
14.1% |
| Death |
11.0% |
| Drug Ineffective |
7.9% |
| Drug Hypersensitivity |
5.8% |
| Loss Of Consciousness |
5.8% |
| Prostatic Disorder |
5.2% |
| Hypotension |
4.7% |
| Presyncope |
4.7% |
| Hypertension |
4.2% |
| Surgery |
4.2% |
| Blood Pressure Increased |
3.7% |
| Dizziness |
3.7% |
| Medication Residue |
3.7% |
| Blood Pressure Decreased |
3.1% |
| Cardiac Failure |
3.1% |
| Dermatitis Exfoliative |
3.1% |
| Urinary Incontinence |
3.1% |
| Urticaria |
3.1% |
| Vision Blurred |
3.1% |
| Cataract Operation |
2.6% |
|
| Secondary |
| Hypertension |
39.9% |
| Product Used For Unknown Indication |
9.5% |
| Benign Prostatic Hyperplasia |
8.6% |
| Drug Use For Unknown Indication |
7.3% |
| Myocardial Ischaemia |
5.3% |
| Atrial Fibrillation |
3.4% |
| Prostatic Disorder |
3.0% |
| Blood Cholesterol Increased |
2.9% |
| Depression |
2.9% |
| Cardiac Disorder |
2.6% |
| Essential Hypertension |
2.1% |
| Ill-defined Disorder |
2.1% |
| Osteoporosis |
1.9% |
| Diabetes Mellitus |
1.6% |
| Anticoagulant Therapy |
1.5% |
| Prostatomegaly |
1.5% |
| Anxiety |
1.0% |
| Arthritis |
1.0% |
| Asthma |
1.0% |
| Blood Cholesterol |
1.0% |
|
| Drug Ineffective |
10.3% |
| Syncope |
8.6% |
| Weight Decreased |
8.6% |
| Deafness |
6.0% |
| Malaise |
6.0% |
| Rash |
6.0% |
| Wrist Fracture |
6.0% |
| Erectile Dysfunction |
5.2% |
| Hypotension |
5.2% |
| Vision Blurred |
5.2% |
| Cerebrovascular Accident |
4.3% |
| Blood Pressure Inadequately Controlled |
3.4% |
| Death |
3.4% |
| Loss Of Consciousness |
3.4% |
| Orthostatic Hypotension |
3.4% |
| Urinary Tract Infection |
3.4% |
| Weight Increased |
3.4% |
| Amnesia |
2.6% |
| Blood Pressure Decreased |
2.6% |
| Drug Eruption |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
27.2% |
| Hypertension |
19.2% |
| Drug Use For Unknown Indication |
13.0% |
| Diabetes Mellitus |
4.8% |
| Blood Pressure |
4.6% |
| Pain |
3.5% |
| Nuclear Magnetic Resonance Imaging |
3.0% |
| Type 2 Diabetes Mellitus |
2.5% |
| Atrial Fibrillation |
2.4% |
| Blood Cholesterol Increased |
2.1% |
| Rheumatoid Arthritis |
2.0% |
| Benign Prostatic Hyperplasia |
2.0% |
| Prophylaxis |
2.0% |
| Cardiac Disorder |
1.9% |
| Chronic Obstructive Pulmonary Disease |
1.8% |
| Renal Transplant |
1.7% |
| Osteoporosis |
1.7% |
| Depression |
1.6% |
| Hormone Replacement Therapy |
1.6% |
| Blood Cholesterol |
1.5% |
|
| Weight Decreased |
11.0% |
| Myocardial Infarction |
8.0% |
| Vomiting |
7.3% |
| Drug Ineffective |
6.5% |
| Pain |
5.5% |
| Renal Failure |
5.5% |
| Rash |
5.1% |
| Syncope |
4.8% |
| Pneumonia |
4.6% |
| Weight Increased |
4.6% |
| Nausea |
4.4% |
| Death |
4.2% |
| Oedema Peripheral |
4.1% |
| Somnolence |
3.9% |
| Pyrexia |
3.7% |
| Renal Failure Acute |
3.5% |
| Pruritus |
3.4% |
| Transient Ischaemic Attack |
3.4% |
| Wrist Fracture |
3.4% |
| Dyspnoea |
3.2% |
|
| Interacting |
| Hypertension |
25.7% |
| Bladder Disorder |
14.3% |
| Depression |
8.6% |
| Pain |
8.6% |
| Phaeochromocytoma |
5.7% |
| Thrombosis Prophylaxis |
5.7% |
| Abdominal Pain Upper |
2.9% |
| Anxiety |
2.9% |
| Back Pain |
2.9% |
| Benign Prostatic Hyperplasia |
2.9% |
| Blood Cholesterol Abnormal |
2.9% |
| Cardiac Disorder |
2.9% |
| Dyslipidaemia |
2.9% |
| Hyperuricaemia |
2.9% |
| Obesity |
2.9% |
| Osteoarthritis |
2.9% |
| Smoking Cessation Therapy |
2.9% |
|
| International Normalised Ratio Increased |
14.3% |
| Vision Blurred |
14.3% |
| Anaphylactic Reaction |
7.1% |
| Blood Pressure Inadequately Controlled |
7.1% |
| Drug Interaction |
7.1% |
| Dry Mouth |
7.1% |
| Hypotension |
7.1% |
| Pollakiuria |
7.1% |
| Syncope |
7.1% |
| Therapeutic Response Decreased |
7.1% |
| Urinary Hesitation |
7.1% |
| Urinary Tract Infection |
7.1% |
|
